Goodwin’s rare-disease symposium
Law firm Goodwin hosted its annual Rare Disease Symposium in Boston on February 5, 2025, in honor of Rare Disease Day. Goodwin’s event page describes an afternoon of fireside chats, presentations and networking that brought together patient, research, policy and biotech chief-executive perspectives, with speakers from the U.S. Food and Drug Administration’s Rare Disease Innovation Hub and the National Organization for Rare Disorders among them. Dr. Omar Costilla Reyes attended as founder of Equ Healthcare and thanked Goodwin for hosting the participants; his post places the symposium at Seaport in Boston.
What makes a disease rare
Under the U.S. Orphan Drug Act of 1983, a rare disease is one that affects fewer than 200,000 people in the United States. Each such condition touches few people, but there are many of them, so the field as a whole matters to a large number of patients. Rare diseases pose particular challenges for research: patient populations are small and spread out, natural-history data are limited, and clinical trials are hard to design. The symposium brought scientific, regulatory and patient perspectives together to address them.
A perspective from industry
A talk by Paula Ragan, chief executive of X4 Pharmaceuticals, added an industry perspective. Dr. Costilla Reyes quoted her observation that more than half of the drugs approved by the U.S. Food and Drug Administration are for rare diseases, a disproportionately high rate of success, and recorded it as an interesting insight. The photograph shows the symposium room, with attendees seated at tables facing wall screens that display speaker slides. Dr. Costilla Reyes took part as an attendee.